PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers

被引：2
|
作者：
Stebbing, Justin [1 ]
Ellis, Paul [2 ,3 ]
Tutt, Andrew [4 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Oncol & Surg, London W12 0NN, England
[2] Guys & St Thomas NHS Trust, Dept Oncol, London, England
[3] Kings Coll Hosp, London, England
[4] Guys Hosp, Breakthrough Breast Canc Res Unit, Kings Hlth Partners AHSC, London SE1 9RT, England
来源：
FUTURE ONCOLOGY | 2010年 / 6卷 / 04期
关键词：
breast cancer; BRCA; PARP inhibitor; triple negative; POLY(ADP-RIBOSE) POLYMERASE; RESISTANCE; DNA; REPAIR; MUTATIONS; TUMORS; BRCA1;
D O I：
10.2217/FON.10.27
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：485 / 486
页数：2
相关论文
共 50 条
  • [31] Pathology of BRCA1-and BRCA2-associated breast cancers: known and less known connections
    Fostira, F.
    Fountzila, E.
    Vagena, A.
    Apostolou, P.
    Konstanta, I.
    Papadimitriou, C.
    Razis, E.
    Christodoulou, C.
    Timotheadou, E.
    Mollaki, V.
    Papamentzelopoulou, M.
    Vlachos, I. S.
    Yannoukakos, D.
    Konstantopoulou, I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] BRCA1a has antitumor activity in triple-negative breast cancers
    Yuli, C.
    Shao, N.
    Oprea-Ilies, G.
    Okoli, J.
    Reddy, E. S. P.
    Rao, V. N.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [33] BRCA1a has antitumor activity in triple-negative breast cancers
    C Yuli
    N Shao
    G Oprea-llies
    J Okoli
    ESP Reddy
    VN Rao
    Breast Cancer Research, 9
  • [34] Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1- associated triple-negative breast cancers
    Domagala, Pawel
    Hybiaki, Jolanta
    Rys, Janusz
    Byrski, Tomasz
    Cybulski, Cezary
    Lubinski, Jan
    ONCOTARGET, 2016, 7 (42) : 68662 - 68673
  • [35] BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness
    Domagala, Pawel
    Hybiak, Jolanta
    Cybulski, Cezary
    Lubinski, Jan
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (07) : 1545 - 1550
  • [36] p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
    Tim Crook
    Louise A Brooks
    Susan Crossland
    P Osin
    Karen T Barker
    Joanne Waller
    Elizabeth Philp
    Paul D Smith
    Isik Yulug
    Julian Peto
    Gillian Parker
    Martin J Allday
    Mark R Crompton
    Barry A Gusterson
    Oncogene, 1998, 17 : 1681 - 1689
  • [37] Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study
    Jurgen M. J. Piek
    Bas Torrenga
    Brenda Hermsen
    René H. M. Verheijen
    Ronald P. Zweemer
    Johan J. P. Gille
    Peter Kenemans
    Paul J. van Diest
    Fred H. Menko
    Familial Cancer, 2003, 2 (2) : 73 - 78
  • [38] Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
    Arakelyan, Arsen
    Melkonyan, Ani
    Hakobyan, Siras
    Boyarskih, Uljana
    Simonyan, Arman
    Nersisyan, Lilit
    Nikoghosyan, Maria
    Filipenko, Maxim
    Binder, Hans
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (03) : 1 - 18
  • [39] p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
    Crook, T
    Brooks, LA
    Crossland, S
    Osin, P
    Barker, KT
    Waller, J
    Philp, E
    Smith, PD
    Yulug, I
    Peto, J
    Parker, G
    Allday, MJ
    Crompton, MR
    Gusterson, BA
    ONCOGENE, 1998, 17 (13) : 1681 - 1689
  • [40] "Targeting" Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers
    Nanda, Rita
    SEMINARS IN ONCOLOGY, 2011, 38 (02) : 254 - 262
12345